BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 36451216)

  • 1. Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia.
    Assefa A; Mohammed H; Anand A; Abera A; Sime H; Minta AA; Tadesse M; Tadesse Y; Girma S; Bekele W; Etana K; Alemayehu BH; Teka H; Dilu D; Haile M; Solomon H; Moriarty LF; Zhou Z; Svigel SS; Ezema B; Tasew G; Woyessa A; Hwang J; Murphy M
    Malar J; 2022 Dec; 21(1):359. PubMed ID: 36451216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated malaria in Papua New Guinea.
    Tavul L; Hetzel MW; Teliki A; Walsh D; Kiniboro B; Rare L; Pulford J; Siba PM; Karl S; Makita L; Robinson L; Kattenberg JH; Laman M; Oswyn G; Mueller I
    Malar J; 2018 Oct; 17(1):350. PubMed ID: 30290825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility of Plasmodium falciparum to artemisinins and Plasmodium vivax to chloroquine in Phuoc Chien Commune, Ninh Thuan Province, south-central Vietnam.
    Phong NC; Chavchich M; Quang HH; San NN; Birrell GW; Chuang I; Martin NJ; Manh ND; Edstein MD
    Malar J; 2019 Jan; 18(1):10. PubMed ID: 30654808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High therapeutic efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Somalia.
    Warsame M; Hassan AM; Hassan AH; Jibril AM; Khim N; Arale AM; Gomey AH; Nur ZS; Osman SM; Mohamed MS; Abdulrahman A; Yusuf FE; Amran JGH; Witkowski B; Ringwald P
    Malar J; 2019 Jul; 18(1):231. PubMed ID: 31296223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial.
    van der Pluijm RW; Tripura R; Hoglund RM; Pyae Phyo A; Lek D; Ul Islam A; Anvikar AR; Satpathi P; Satpathi S; Behera PK; Tripura A; Baidya S; Onyamboko M; Chau NH; Sovann Y; Suon S; Sreng S; Mao S; Oun S; Yen S; Amaratunga C; Chutasmit K; Saelow C; Runcharern R; Kaewmok W; Hoa NT; Thanh NV; Hanboonkunupakarn B; Callery JJ; Mohanty AK; Heaton J; Thant M; Gantait K; Ghosh T; Amato R; Pearson RD; Jacob CG; Gonçalves S; Mukaka M; Waithira N; Woodrow CJ; Grobusch MP; van Vugt M; Fairhurst RM; Cheah PY; Peto TJ; von Seidlein L; Dhorda M; Maude RJ; Winterberg M; Thuy-Nhien NT; Kwiatkowski DP; Imwong M; Jittamala P; Lin K; Hlaing TM; Chotivanich K; Huy R; Fanello C; Ashley E; Mayxay M; Newton PN; Hien TT; Valecha N; Smithuis F; Pukrittayakamee S; Faiz A; Miotto O; Tarning J; Day NPJ; White NJ; Dondorp AM;
    Lancet; 2020 Apr; 395(10233):1345-1360. PubMed ID: 32171078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial.
    West African Network for Clinical Trials of Antimalarial Drugs (WANECAM)
    Lancet; 2018 Apr; 391(10128):1378-1390. PubMed ID: 29606364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax malaria in Papua and Sumatra, Indonesia.
    Asih PBS; Rozi IE; Dewayanti FK; Wangsamuda S; Zulfah S; Robaha M; Hutahaean J; Anggraeni ND; Kusumaningsih M; Mulyani PS; Sariwati E; Basri HH; Bustos MDG; Syafruddin D
    Malar J; 2022 Mar; 21(1):95. PubMed ID: 35305658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic efficacy of dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium vivax malaria in Seacha area, Arbaminch Zuria District, South West Ethiopia.
    Mohammed H; Sime H; Hailgiorgis H; Gubae K; Haile M; Solomon H; Etana K; Girma S; Bekele W; Chernet M; Tollera G; Tasew G; Gidey B; Commons RJ; Assefa A
    Malar J; 2022 Nov; 21(1):351. PubMed ID: 36437454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children.
    Nambozi M; Van Geertruyden JP; Hachizovu S; Chaponda M; Mukwamataba D; Mulenga M; Ubben D; D'Alessandro U
    Malar J; 2011 Feb; 10():50. PubMed ID: 21352609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial of dihydroartemisinin-piperaquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali.
    Dama S; Niangaly H; Djimde M; Sagara I; Guindo CO; Zeguime A; Dara A; Djimde AA; Doumbo OK
    Malar J; 2018 Oct; 17(1):347. PubMed ID: 30290808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A trial of combination antimalarial therapies in children from Papua New Guinea.
    Karunajeewa HA; Mueller I; Senn M; Lin E; Law I; Gomorrai PS; Oa O; Griffin S; Kotab K; Suano P; Tarongka N; Ura A; Lautu D; Page-Sharp M; Wong R; Salman S; Siba P; Ilett KF; Davis TM
    N Engl J Med; 2008 Dec; 359(24):2545-57. PubMed ID: 19064624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison.
    Ratcliff A; Siswantoro H; Kenangalem E; Maristela R; Wuwung RM; Laihad F; Ebsworth EP; Anstey NM; Tjitra E; Price RN
    Lancet; 2007 Mar; 369(9563):757-765. PubMed ID: 17336652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of parasite genomic dynamics on the sensitivity of Plasmodium falciparum isolates to piperaquine and other antimalarial drugs.
    Wakoli DM; Ondigo BN; Ochora DO; Amwoma JG; Okore W; Mwakio EW; Chemwor G; Juma J; Okoth R; Okudo C; Yeda R; Opot BH; Cheruiyot AC; Juma D; Roth A; Ogutu BR; Boudreaux D; Andagalu B; Akala HM
    BMC Med; 2022 Nov; 20(1):448. PubMed ID: 36397090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled trial of dihydroartemisinin-piperaquine, artesunate-mefloquine and extended artemether-lumefantrine treatments for malaria in pregnancy on the Thailand-Myanmar border.
    Saito M; Carrara VI; Gilder ME; Min AM; Tun NW; Pimanpanarak M; Viladpai-Nguen J; Paw MK; Haohankhunnatham W; Konghahong K; Phyo AP; Chu C; Turner C; Lee SJ; Duanguppama J; Imwong M; Bancone G; Proux S; Singhasivanon P; White NJ; Nosten F; McGready R
    BMC Med; 2021 Jun; 19(1):132. PubMed ID: 34107963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. UK malaria treatment guidelines 2016.
    Lalloo DG; Shingadia D; Bell DJ; Beeching NJ; Whitty CJM; Chiodini PL;
    J Infect; 2016 Jun; 72(6):635-649. PubMed ID: 26880088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial.
    Abreha T; Hwang J; Thriemer K; Tadesse Y; Girma S; Melaku Z; Assef A; Kassa M; Chatfield MD; Landman KZ; Chenet SM; Lucchi NW; Udhayakumar V; Zhou Z; Shi YP; Kachur SP; Jima D; Kebede A; Solomon H; Mekasha A; Alemayehu BH; Malone JL; Dissanayake G; Teka H; Auburn S; von Seidlein L; Price RN
    PLoS Med; 2017 May; 14(5):e1002299. PubMed ID: 28510573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimalarial drug efficacy and resistance in malaria-endemic countries in HANMAT-PIAM_net countries of the Eastern Mediterranean Region 2016-2020: Clinical and genetic studies.
    Adam M; Nahzat S; Kakar Q; Assada M; Witkowski B; Tag Eldin Elshafie A; Abuobaida D; Safi N; Khan MA; Nagi M; Mustafa SA; Kohestani K; Muhammad J; Khim N; Al-Hadi M; Elfaki TM; Habib MN; Khairy AKA; Hamid H; Uddin Z; Amer Y; Hassan AH; Elhag MS; Sediqi AW; Kakar I; Abdul-Ghani R; Amran JGH; Abdallrahim TA; Tamim MS; Aljasari A; Rasmussen C; Azkoul L; Warsame M
    Trop Med Int Health; 2023 Oct; 28(10):817-829. PubMed ID: 37705047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of artesunate-amodiaquine, dihydroartemisinin-piperaquine and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Maradi, Niger.
    Grandesso F; Guindo O; Woi Messe L; Makarimi R; Traore A; Dama S; Laminou IM; Rigal J; de Smet M; Ouwe Missi Oukem-Boyer O; Doumbo OK; Djimdé A; Etard JF
    Malar J; 2018 Jan; 17(1):52. PubMed ID: 29370844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo efficacy of artemether-lumefantrine and chloroquine against Plasmodium vivax: a randomized open label trial in central Ethiopia.
    Hwang J; Alemayehu BH; Reithinger R; Tekleyohannes SG; Takele Teshi ; Birhanu SG; Demeke L; Hoos D; Melaku Z; Kassa M; Jima D; Malone JL; Nettey H; Green M; Poe A; Akinyi S; Udhayakumar V; Kachur SP; Filler S
    PLoS One; 2013; 8(5):e63433. PubMed ID: 23717423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria among children in Africa: a systematic review and meta-analysis of randomized control trials.
    Assefa DG; Yismaw G; Makonnen E
    Malar J; 2021 Aug; 20(1):340. PubMed ID: 34384431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.